Recursion, a biopharma company, uses a data-driven approach to drug discovery, launching four clinical trials and planning a fifth in oncology. Recursion's software platform, the Recursion OS, is used ...

If it can bounce back and generate solid returns in the next five years, now is about as good a time as any to invest in the ...

Recursion's stock has been consistently rated as "Hold" by this analyst due to skepticism about its AI-driven drug discovery approach and its financial instability. The company's IPO raised over $500 ...

Researchers at the University of Tübingen have found via experimentation that crows are capable of understanding the concept of recursion. In their paper published in the journal Science Advances, ...

This paper deals with a philosophical question that arises within the theory of computational complexity: how to understand the notion of INTRINSIC complexity or difficulty, as opposed to notions of ...

The results of a recent survey released Tuesday showed President Trump's actions are likely to make it harder for biotech companies like Recursion to raise capital. The company reported ...